Please assess the completion status of the following clinical trial:

Trial Title: Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 16.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 years or older. Female subjects must be either post-menopausal for one year, surgically sterile, or using an effective contraceptive method. Hormonal contraceptive use is disallowed.~* Subjects must have mild to moderate essential hypertension (Grade 1 and 2 WHO classifications) as measured by calibrated standard sphygmomanometer. (MSDBP of ≥90 mmHg and \< 110 mmHg at Visit 1 (placebo run-in), and MSDBP of ≥95 mmHg and \< 110 mmHg at visit 2 (randomization)~* Subjects must have an absolute difference in their MSDBP of less than 10 mmHg between Visit 1 (placebo run- in) and Visit 2 (randomization).~Exclusion Criteria:~* Severe hypertension (Grade 3 WHO classification; MSDBP ≥110 mmHg and/or MSSBP ≥ 180 mmHg)~* Inability to washout of antihypertensive drugs (even if prescribed for another indication) safely for a period of 14 weeks.~* History of hypertensive retinopathy - known Keith-Wagener Grade III or IV~* History of hypertensive encephalopathy~* Cerebrovascular ischemic event (stroke, transient ischemic attack \[TIA\])within the previous 12 months~* History of intracerebral hemorrhage or subarachnoid hemorrhage~* Evidence of secondary hypertension such as coarchation of the aorta, pheochromocytoms, hypersaldosteronism, etc.~* Type I diabetes mellitus (DM) or poorly controlled DM Type II as evidenced by a glycosylated hemoglobin \[HbA1C\] of greater than 9% on visit 1.~* Allergies or known intolerance to one of the investigational drugs/drug class or to one of their ingredients~* Any history of heart failure, New York Heart Association (NYHA) classification III or IV~* Severe coronary heart disease as manifest by a history of myocardial infarction or unstable angina in the last 6 months prior to visit 1.~* Clinically significant cardiac valvular disease~* History of malignancy in the last 5 years, excluding basal or skin cancer~* Uncorrected hypokalemia or hyperkalemia: potassium outside 3.0-5.0 mmol/L~* Surgical or medical conditions that might alter the metabolism, excretion or distribution or absorption of any drug~  1. Gastrointestinal disease or surgery resulting in the potential for malabsorption~ 2. Severe gastrointestinal tract narrowing; kock pouch (ileostomy after proctocolectomy)~ 3. Cholestasis or biliary obstruction or history of pancreatic injury or clinical significant increase of lipase, amylase, or bilirubin.~ 4. Liver disease or AST/ALT levels \>3 x ULN~ 5. Renal insufficiency, defined as eGFR of \< 50 mL/min (computed using the Cockroft-Gault formula), or on hemodialysis~* Investigation trial participation with receipt of investigational study drug within the last month~* Previous assignment to treatment in this study~* Female subjects who are pregnant or lactating.~* Subjects who have night employment (night shift).~* Subjects with an aortic aneurysm that, in the opinion of the investigator, will be unsuitable to be enrolled in the study.~* Thought by the investigator for any reason to be unsuitable for participation in a clinical study~* Systemic use of known cytochrome P450-3A4 inhibitors (e.g cimetidine, anti-human immunodeficiency virus \[HIV\] protease inhibitors e.g. ritonavir, azole anti-mycotics eg. ketoconazole,) or inducers (e.g rifampicin, anti-epileptic drugs eg. phenytoin, carbamazepine and phenobarbitone) or some P450-3A4 substrates (e.g quinidine, digoxin, tacrolimus)~* Present severe rhythm or conduction disorder:~* Atrial fibrillation~* Second or third degree heart block without a pacemaker.~* Baseline QTc \>450 msec~* History of non-compliance, alcoholism or drug abuse that in the opinion of the investigator will compromise successful completion of the study.~* If differences greater than 20 mmHg for SBP and 10 mmHg for DBP are present on 3 consecutive BP readings, the subject should be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nifedipine GITS 20 mg (Type: EXPERIMENTAL): Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
- Nifedipine GITS 30 mg (Type: EXPERIMENTAL): Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
- Nifedipine GITS 60 mg (Type: EXPERIMENTAL): Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
- Candesartan cilexetil 4 mg (Type: EXPERIMENTAL): Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
- Candesartan cilexetil 8 mg (Type: EXPERIMENTAL): Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
- Candesartan cilexetil 16 mg (Type: EXPERIMENTAL): Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
- Candesartan cilexetil 32 mg (Type: EXPERIMENTAL): Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
- Nifedipine/candesartan 20/4 mg (Type: EXPERIMENTAL): Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 20/8 mg (Type: EXPERIMENTAL): Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 20/16 mg (Type: EXPERIMENTAL): Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 30/8 mg (Type: EXPERIMENTAL): Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 30/16 mg (Type: EXPERIMENTAL): Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 30/32 mg (Type: EXPERIMENTAL): Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 60/16 mg (Type: EXPERIMENTAL): Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Nifedipine/candesartan 60/32 mg (Type: EXPERIMENTAL): Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).